Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC

Experimental Biology and Medicine

Volumn 233, Issue 7, 2008, Pages 860-873

  Arnold, Shanna ^a   Mira, Emilia ^b   Muneer, Sabeeha ^a   Korpanty, Grzegorz ^a   Beck, Adam W ^a   Holloway, Shane E ^a   Mañes, Santos ^b   Brekken, Rolf A ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ECM; pancreatic; metastasis; MMP9; SPARC; Tumor microenvironment

Indexed keywords

GELATINASE B; OSTEONECTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; METASTASIS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ADENOCARCINOMA; ANIMAL; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA; MURINAE; MUS;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OSTEONECTIN; PANCREATIC NEOPLASMS;

EID: 47749119594     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0801-RM-12     Document Type: Article

References (48)

1. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19:816-827, 2001.
2. Bornstein P. Cell-matrix interactions: the view from the outside. Methods Cell Biol 69:7-11, 2002.
3. Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix interactions. Faseb J 8:163-173, 1994.
4. Liaw L, Crawford HC. Functions of the extracellular matrix and matrix degrading proteases during tumor progression. Braz J Med Biol Res 32: 805-812, 1999.
5. Motamed K, Sage EH. Regulation of vascular morphogenesis by the matricellular protein SPARC. Kidney Int 51:1383-1387, 1997.
6. Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 77:465-480, 1999.
7. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis 14:246-258, 1994.
8. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcino- genesis. Nat Cell Biol 2:737-744, 2000.
9. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561-573, 2002.
10. Chantrain CF, Shimada H, Jodele S, Groshen S, Ye W, Shalinsky DR, Werb Z, Coussens LM, DeClerck YA. Stromal matrix metalloprotein-ase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 64:1675-1686, 2004.
11. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 92:679-690, 2004.
12. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12:1895-1901, 1996.
13. Brown TJ, Shaw PA, Karp X, Huynh MH, Begley H, Ringuette MJ. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 75:25-33, 1999.
14. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH, Goggins M. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22:5021-5030, 2003.
15. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63:5376-5380, 2003.
16. Puolakkainen PA, Brekken RA, Muneer S, Sage EH. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2:215-224, 2004.
17. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111:487-495, 2003.
18. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23:953-964, 2005.
19. Sasaki T, Hohenester E, Gohring W, Timpl R. Crystal structure and mapping by site-directed mutagenesis of the collagen-binding epitope of an activated form of BM- 40/SPARC/osteonectin. Embo J 17:1625-1634, 1998.
20. Sasaki T, Miosge N, Timpl R. Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biol 18:499-508, 1999.
21. Sage EH, Reed M, Funk SE, Truong T, Steadele M, Puolakkainen P, Maurice DH, Bassuk JA. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 278:37849-37857, 2003.
22. Mira E, Lacalle RA, Gonzalez MA, Gomez-Mouton C, Abad JL, Bernad A, Martinez AC, Manes S. A role for chemokine receptor transactivation in growth factor signaling. EMBO Rep 2:151-156, 2001.
23. Sweetwyne MT, Brekken RA, Workman G, Bradshaw AD, Carbon J, Siadak AW, Murri C, Sage EH. Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem 52:723-733, 2004.
24. Quesada AR, Barbacid MM, Mira E, Fernandez-Resa P, Marquez G, Aracil M. Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases. Clin Exp Metastasis 15:26-32, 1997.
25. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sage EH, Howe CC. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 39:2674-2680, 1998.
26. Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1:50-62, 1999.
27. Bernstein EF, Chen YQ, Kopp JB, Fisher L, Brown DB, Hahn PJ, Robey FA, Lakkakorpi J, Uitto J. Long-term sun exposure alters the collagen of the papillary dermis. Comparison of sun-protected and photoaged skin by northern analysis, immunohistochemical staining, and confocal laser scanning microscopy. J Am Acad Dermatol 34:209-218, 1996.
28. Bernstein EF, Fisher LW, Li K, LeBaron RG, Tan EM, Uitto J. Differential expression of the versican and decorin genes in photoaged and sun-protected skin. Comparison by immunohistochemical and northern analyses. Lab Invest 72:662-669, 1995.
29. Hallmann R, Mayer DN, Berg EL, Broermann R, Butcher EC. Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier. Dev Dyn 202:325-332, 1995.
30. Mira E, Lacalle RA, Gomez-Mouton C, Leonardo E, Manes S. Quantitative determination of tumor cell intravasation in a real-time polymerase chain reaction-based assay. Clin Exp Metastasis 19:313-318, 2002.
31. Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T, Quigley JP. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 65:10959-10969, 2005.
32. Zar JH. Biostatistical Analysis (4th ed.). New Jersey: Prentice Hall. 1999.
33. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcino- genesis. Proc Natl Acad Sci U S A 103:12493-12498, 2006.
34. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26: 716-728, 2006.
35. Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94:353-362, 1998.
36. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 363: 1049-1057, 2004.
37. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22:6524-6536, 2003.
38. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76(Spec No 1):S11-22, 2003.
39. Ludwig T. Local proteolytic activity in tumor cell invasion and metastasis. Bioessays 27:1181-1191, 2005.
40. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25:319-325, 2007.
41. Sasaki T, Gohring W, Mann K, Maurer P, Hohenester E, Knauper V, Murphy G, Timpl R. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J Biol Chem 272:9237-9243, 1997.
42. McClung HM, Thomas SL, Osenkowski P, Toth M, Menon P, Raz A, Fridman R, Rempel SA. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett 419:172-177, 2007.
43. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 58:5529-5536, 1998.
44. Fujita T, Shiba H, Sakata M, Uchida Y, Nakamura S, Kurihara H. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. J Oral Pathol Med 31:345-352, 2002.
45. Guweidhi A, Kleeff J, Adwan H, Giese NA, Wente MN, Giese T, Buchler MW, Berger MR, Friess H. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 242:224-234, 2005.
46. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 21:272-281, 2002.
47. Chen X, Su Y, Fingleton B, Acuff H, Matrisian LM, Zent R, Pozzi A. Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells. Int J Cancer 116:52-61, 2005.
48. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, Hynes RO, Werb Z, Sudhakar A, Kalluri R. Physiological levels of tumstatin, a fragment of collagen IV [alpha]3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via [alpha]V[beta]3 integrin. Cancer Cell 3:589-601, 2003.